Real-World Outcomes of Patients with Refractory or Relapsed <i>FLT3</i>-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study

Real-World Outcomes of Patients with Refractory or Relapsed <i>FLT3</i>-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study

Two recent phase 3 trials showed that outcomes for relapsed/refractory (R/R) <i>FLT3</i>-mutated acute myeloid leukemia (AML) patients may be improved by a single-agent tyrosine kinase inhibitor (TKI) (i.e., quizartinib or gilteritinib). In the current study, we retrospectively investiga...

Full description

Bibliographic Details
Main Authors: Pierre-Yves Dumas, Sarah Bertoli, Emilie Bérard, Laetitia Largeaud, Audrey Bidet, Eric Delabesse, Thibaut Leguay, Harmony Leroy, Noémie Gadaud, Jean Baptiste Rieu, Jean-Philippe Vial, François Vergez, Nicolas Lechevalier, Isabelle Luquet, Emilie Klein, Audrey Sarry, Anne-Charlotte de Grande, Arnaud Pigneux, Christian Récher
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Cancers
Subjects:
acute myeloid leukemia
FLT3-ITD mutation
primary induction failure
relapse
tyrosine kinase inhibitors
Online Access:https://www.mdpi.com/2072-6694/12/8/2044

Internet

https://www.mdpi.com/2072-6694/12/8/2044

Similar Items